Levofloxacin Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Levofloxacin Market Analysis
Over the next few years, the levofloxacin market is expected to register a CAGR of 5.1%.
The COVID-19 pandemic significantly impacted healthcare systems, with significant consequences for the global population. Due to the cancellation of treatment to manage and reserve resources, healthcare services were controlled. Many hospitals experienced a shortage of professionals to assist with the burden of the pandemic and associated diseases. Thus, the demand for levofloxacin initially decreased due to a decrease in hospital visits.
However, during the later phases of the pandemic, there was a huge demand for antibiotics, which considerably impacted the studied market growth. For instance, according to an article published in the BioMed Central (BMC) journal in May 2021, levofloxacin was among the most commonly used antibiotics for the clinical management of COVID-19, along with other antibiotics. Hence, it is observed that with the use of levofloxacin in COVID management, the market witnessed slight growth during the pandemic. Thus, the pandemic had an effect on the growth of the market, and it is expected that the market will continue to grow over the study period.
During the forecast period, the market is expected to grow because of things like the growing burden of nosocomial and community-acquired pneumonia, the rising number of bacterial infections, and the fact that drugs are easy to get and not too expensive.
In addition, the increasing prevalence of bacterial diseases is one of the key factors responsible for the growth of the market studied. For instance, according to the October 2021 update of the WHO, most tuberculosis (TB) cases were found in the regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of TB cases were found in the Eastern Mediterranean (8.3%), the Americas (3.0%), and Europe (2.3%). The statistics show that the TB burden is high across all regions, which is expected to drive market growth because Levofloxacin is widely used in the treatment of TB. This is predicted to contribute to the market's growth over the forecast period.
But one of the biggest things slowing market growth around the world is that most people don't know much about infectious diseases.
Levofloxacin Market Trends
This section covers the major market trends shaping the Levofloxacin Market according to our research experts:
Pneumonia Segment is Expected to Significant Market Share
The pneumonia segment is expected to grow significantly and hold a major share of the global levofloxacin market throughout the forecast period. The increasing incidence of pneumococcal disease is a high-impact driver. Over the years, there has been a significant upsurge in the number of community-acquired and ventilator-associated bacterial pneumonias.
The burden of pneumonia is on the rise among the global population, creating demand for levofloxacin for treatment purposes. As per an article published in the International Journal of Pediatrics in December 2021, community-acquired pneumonia is one of the major causes of hospitalizations among children worldwide, and the incidence of the disease is highest among children under 5 years. Similarly, in a study published in Frontiers in Pediatrics in February 2022, the prevalence of hypoxic pneumonia was found to be around 35.9% across the North Indian region. Hence, the high incidence and prevalence of the disease are contributing to the increased demand for antibiotic drugs such as levofloxacin across Asian countries.
In addition, according to the research paper on community-acquired pneumonia updated in November 2022 in the NLM journal, community-acquired pneumonia is a leading cause of hospitalization and mortality and incurs high healthcare costs in the United States. As diseases can range from being mild enough to be treated as an outpatient to being so serious that they need to be treated in the intensive care unit, figuring out the right level of care is important for improving outcomes, making sure early diagnosis, and giving the right treatment at the right time.
Also, as per the above-mentioned source, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 and 14 cases per 1,000 persons per year, which is affected by geography, season, and population characteristics. Additionally, according to the same source, in the United States, the annual incidence is 24.8 cases per 10,000 adults; the rates are higher with the increase in age, and the mortality rate is as high as 23% for patients admitted to the intensive care unit. Such studies show that pneumonia-related illnesses are common, which is likely to increase the number of therapeutics for pneumonia around the world and speed up the growth of this segment.
North America is Expected to Hold a significant Market Share
North America has a big share of the market that was looked at. This is because there are a lot of big market players there and more people are getting chronic and infectious diseases like pneumonia, kidney diseases, and bladder infections.Furthermore, factors such as treatment costs, technological advancements, and product launches are expected to drive regional growth. Also, different government programs that try to prevent and treat pneumonia are making a positive difference across North America.
According to the November 2022 update by the CDC, approximately 7,171 (2.2 cases per 100,000 population) new cases of TB were reported in the United States in 2020, which increased to 7,882 (2.4 cases per 100,000 population) in 2021. According to the same source, the prevalence of tuberculosis was highest among Hispanic or Latino people, who accounted for roughly 30% of all TB cases reported in the country.A high prevalence of TB is believed to result in increased demand for levofloxacin in the country, fueling overall market growth in the region.
Additionally, the burden of the geriatric population has been increasing recently in the region. For instance, according to the 2022 statistics published by UNPF, in the United States, a large proportion of the population is aged 15-64 years and is expected to account for 65% in 2022. In addition, as per the same source, 17% of the population will be 65 years of age or older by the end of 2022. Thus, the increasing geriatric population has a high risk of getting infections due to their low immunity, which increases the demand for antibiotic drugs such as levofloxacin, thereby increasing market growth.
Hence, with the abovementioned factors, the market for levofloxacin is expected to witness strong growth in the North American region, and the United States is believed to hold a significant share among other countries in North America.
Levofloxacin Industry Overview
The market for levofloxacin is consolidated and consists of global as well as local players. The consolidated environment is marked by key players extensively deploying sustainability strategies. Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., and Zydus Cadila are some of the most notable companies. These companies are involved in new product development initiatives, mergers and acquisitions, and geographical expansion.
Levofloxacin Market Leaders
-
Zydus Cadila
-
Dr. Reddy's Laboratories Ltd.
-
LUPIN LIMITED
-
PAX HEALTHCARE
-
Allenge India Pharma
*Disclaimer: Major Players sorted in no particular order
Levofloxacin Market News
- August 2022: Santen launched Ducressa in the United Kingdom and Ireland. The therapy is a fixed-dose combination of levofloxacin and dexamethasone for use after cataract surgery. This is part of a convenient seven-day therapeutic strategy to optimize post-surgery care.
- February 2022: Russia's Binnopharm Group and India's Dr. Reddy's Laboratories announced that they had signed a deal that would allow Binnopharm Group to buy antibacterial medicines from Dr. Reddy's in Russia, Uzbekistan, and Belarus. These medicines are sold under the brand names Ciprolet (ciprofloxacin) and Levolet (levofloxacin).
Levofloxacin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Burden of Nosocomial and Community-acquired Pneumonia
- 4.2.2 Growing Incidence of Bacterial Infections
- 4.2.3 Easy Availability and Affordable Cost of Drugs
-
4.3 Market Restraints
- 4.3.1 Lack of Awareness about Infectious Diseases
- 4.3.2 Adverse Reactions Associated with Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Type
- 5.1.1 250 mg Tablets
- 5.1.2 500 mg Tablets
- 5.1.3 750 mg Tablets
-
5.2 By Application
- 5.2.1 Pneumonia
- 5.2.2 Skin Infection
- 5.2.3 Kidney Infection
- 5.2.4 Bladder Infection
- 5.2.5 Other Applications
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Online Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Aden Healthcare
- 6.1.2 Allenge India Pharma
- 6.1.3 Alna Biotech Private Limited
- 6.1.4 Cipla Ltd
- 6.1.5 DivineSavior.in
- 6.1.6 Dr. Reddy's Laboratories Ltd.
- 6.1.7 Glenmark Pharmaceuticals
- 6.1.8 Lupin Limited
- 6.1.9 PAX HEALTHCARE
- 6.1.10 Zhejiang Jingxin Pharmaceutical Co., Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLevofloxacin Industry Segmentation
As per the scope of the report, levofloxacin is used for the treatment of bacterial infections in various parts of the body. It is also used for the treatment of anthrax infection after inhalational exposure. Levofloxacin is also used to treat and prevent plagues (including pneumonic and septicemic plagues) and is approved for the treatment of pneumonia of various types. The levofloxacin market is segmented by type (250 mg tablets, 500 mg tablets, and 750 mg tablets), application (pneumonia, skin infections, kidney infections, bladder infections, and other applications), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | 250 mg Tablets | |
| 500 mg Tablets | ||
| 750 mg Tablets | ||
| By Application | Pneumonia | |
| Skin Infection | ||
| Kidney Infection | ||
| Bladder Infection | ||
| Other Applications | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Levofloxacin Market Research FAQs
What is the current Global Levofloxacin Market size?
The Global Levofloxacin Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)
Who are the key players in Global Levofloxacin Market?
Zydus Cadila , Dr. Reddy's Laboratories Ltd. , LUPIN LIMITED , PAX HEALTHCARE and Allenge India Pharma are the major companies operating in the Global Levofloxacin Market.
Which is the fastest growing region in Global Levofloxacin Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Levofloxacin Market?
In 2024, the North America accounts for the largest market share in Global Levofloxacin Market.
What years does this Global Levofloxacin Market cover?
The report covers the Global Levofloxacin Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Global Levofloxacin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Levofloxacin Industry Report
Statistics for the 2024 Levofloxacin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Levofloxacin analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
